TE
Therapeutic Areas
Arcutis Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Topical Roflumilast Cream 0.3% (ZORYVE) | Plaque Psoriasis (Adults & Adolescents) | Approved |
| Topical Roflumilast Cream 0.3% | Plaque Psoriasis (Children 2-5 years) | sNDA Submitted |
| Topical Roflumilast Cream 0.15% (ZORYVE) | Atopic Dermatitis (Adults & Adolescents) | Approved |
| Topical Roflumilast Cream 0.05% | Atopic Dermatitis (Children 3-24 months) | Phase 2 |
| Topical Roflumilast Foam 0.3% (ZORYVE) | Seborrheic Dermatitis | Approved |
| Topical Roflumilast Foam 0.3% | Scalp and Body Psoriasis | Phase 3 Completed |
| ARQ-234 | Atopic Dermatitis | Preclinical/Phase 1 |
Leadership Team at Arcutis Biotherapeutics
FW
Frank Watanabe
President and Chief Executive Officer
PB
Patrick Burnett
Chief Medical Officer
DT
David Topper
Chief Financial Officer
DD
Derek DiRocco
Senior Vice President, Research & Development
SB
Scott Burrows
Chief Operating Officer and Chief Financial Officer (former)